Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study.

Laura MühlEmily BeckerTanja M MüllerRaja AtreyaImke AtreyaMarkus F NeurathSebastian Zundler

Published in: BMC gastroenterology (2021)

Our study confirms that vedolizumab is an efficient option for the treatment of UC and CD. Clinical parameters of disease activity may help to predict the success of treatment.

Keyphrases

chronic kidney disease
end stage renal disease
disease activity
rheumatoid arthritis
ulcerative colitis
mental health
rheumatoid arthritis patients
ankylosing spondylitis
combination therapy
ejection fraction
patient reported